EuroBiotech: More Articles of Note


> Affimed dosed the first patient in a phase 1/2a clinical trial of its innate cell redirecting immuno-oncology candidate AFM24. The trial is enrolling patients with solid tumors that express EGFR. Release 

> The FDA accepted Autolus Therapeutics’ filing to study AUTO1 in adults with acute lymphoblastic leukemia. Autolus expects COVID-19 to have minimal impact on the study. Statement  

> Synthon Biopharmaceuticals rebranded as Byondis. The Dutch biotech is closing in on data from a phase 3 trial of its anti-HER2 antibody-drug conjugate SYD985. Release 

> Mayne Pharma filed for FDA approval of E4/DRSP, a combined oral contraceptive that is partnered with Belgium’s Mithra Pharmaceuticals. Statement 

> Kymab claimed a win in its patent dispute with Regeneron. The case centers on patents for genetically modified mice and antibodies taken from them. Release 

> Sosei Heptares began applying its structure-based drug design platform to the discovery of inhibitors of SARS-CoV-2 protease. The biotech will make its findings freely available. Statement